A decades-old blood pressure drug, hydralazine, may slow the growth of deadly brain cancer, new research shows. Scientists found it targets the ADO enzyme, which helps glioblastoma cells survive low oxygen. By blocking ADO, the drug stops tumour cells from dividing. While results are promising, tests on animals and humans are still needed.